RXRX|Analyst Targets
RXRX|Company Info
RXRX|Insider Trading
RXRX|Fundamentals
RXRX|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $-0.23 | - | - |
| Q2'26 | $-0.24 | $-0.25 | -4.7% |
| Q1'26 | $-0.26 | $-0.22 | +14.4% |
| Q4'25 | $-0.32 | $-0.21 | +33.3% |
| Q3'25 | $-0.38 | $-0.36 | +5.7% |
| Q2'25 | $-0.35 | $-0.41 | -16.0% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $13M | - | - |
| Q2'26 | $12M | $8M | -37.1% |
| Q1'26 | $16M | $6M | -59.0% |
| Q4'25 | $25M | $36M | +44.7% |
| Q3'25 | - | $5M | - |
| Q2'25 | - | $19M | - |
RXRX|Monthly Returns
Market Data
RXRX Stock Snapshot
- Market cap
- 2.06B
- Day range
- $3.66 – $3.96
- News sentiment
- 70/100 · Bullish
- Analyst target
- $7.22 (+93.0%)
- Consensus
- Buy · 15 analysts
RXRX's technical picture is under pressure, with momentum working against price. Position sizing matters more than usual in a name this size, where volatility is structural.
Behaviour On Record
What RXRX's own history says about today's numbers
- Realized volatility (21d)
- 106.7% 77th pct
- Below its peak
- -90.6%
- vs 200-day average
- +9.4%
- Up days (1y)
- 42%
Recursion Pharmaceuticals Inc. is currently running 106.7% annualised volatility over the last 21 sessions. Measured against RXRX's own 5 years of daily returns rather than a market-wide average, that is the 77th percentile — elevated for this stock, against a typical reading of 83.1%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
RXRX is trading -90.6% below its running peak. Across 4 full years on file, its median worst-drawdown-in-a-year was -63.3%, and the deepest was -71.8% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits +9.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 86th percentile — a wider gap than this stock usually carries. Over the past year RXRX closed higher on 42% of sessions, and it is currently 1 session into a rising streak.
On October specifically: over 6 years of records, RXRX finished the month higher 2 of 6 times, with a median return of -4.8% and an average of -5.9%. Its strongest month historically has been June at +8.9% on average, its weakest March at -22.4%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: RXRX has opened more than 2% away from the prior close in 262 of 1,361 sessions (19.3% of the time), with the largest gaps running +10.6% and -18.0%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, RXRX moved an average of 1.5% in the session after earnings, closing higher 1 of those 3 times, with a median move of -1.3% and a largest of -3.0%.
All figures computed from 1,363 daily closes between 2021-04-16 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against RXRX's own 6-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of RXRX's sector?
Recursion Pharmaceuticals Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Biotechnology industry group, RXRX ranks 9th of 15 tracked industries, improving.
- Sector rank
- #2 of 12
- Sector state
- Leading
- Sector rotation score
- 82
- Industry rank
- #9 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on RXRX?
Morgan Stanley most recently reiterated its rating on Recursion Pharmaceuticals Inc. to Equal-Weight on May 14, 2026 with a price target of $6 (from $5). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- Morgan Stanley — Equal-Weight
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Peers & ETF holders
RXRX peers & ETF holders
BiotechnologyMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▲ Buy | 47,187,759 | 8.90% | $193.00M | 2026-01-29 |
| BlackRock, Inc. | ▲ Buy | 50,304,691 | 9.49% | $184.62M | 2026-08-07 |
| Baillie Gifford & Co | ▼ Sell | 23,487,907 | 4.43% | $86.20M | 2026-08-06 |
| Geode Capital Management, LLC | ▲ Buy | 13,819,135 | 2.61% | $50.72M | 2026-08-12 |
| Norges Bank | ▲ Buy | 6,833,534 | 1.29% | $25.08M | 2026-08-12 |
| Northern Trust Corp | ▲ Buy | 4,758,236 | 0.90% | $17.46M | 2026-08-13 |
| Marshall Wace, LLP | ▲ Buy | 4,714,577 | 0.89% | $17.30M | 2026-08-13 |
| Goldman Sachs Group Inc | ▼ Sell | 3,917,858 | 0.74% | $14.38M | 2026-08-14 |
| Two Sigma Investments, LP | ▼ Sell | 3,353,658 | 0.63% | $12.31M | 2026-08-14 |
| Susquehanna International Group, LLP | ▼ Sell | 3,292,128 | 0.62% | $12.08M | 2026-08-14 |
| Morgan Stanley | ▲ Buy | 2,743,499 | 0.52% | $10.07M | 2026-08-13 |
| Bank of America Corp | ▲ Buy | 2,597,478 | 0.49% | $9.53M | 2026-08-14 |
| Millennium Management LLC | ▼ Sell | 1,834,762 | 0.35% | $6.73M | 2026-08-14 |
| JPMorgan Chase & Co | ▼ Sell | 1,146,516 | 0.22% | $4.32M | 2026-08-12 |
| Citigroup Inc | ▲ Buy | 864,403 | 0.16% | $3.17M | 2026-08-03 |
| Invesco Ltd. | ▲ Buy | 795,698 | 0.15% | $2.92M | 2026-08-14 |
| Man Group plc | ▼ Sell | 765,786 | 0.14% | $2.81M | 2026-08-14 |
| Wells Fargo & Company | ▲ Buy | 510,879 | 0.10% | $1.87M | 2026-08-14 |
| Verition Fund Management LLC | ▲ Buy | 446,947 | 0.08% | $1.64M | 2026-08-14 |
| AQR Capital Management LLC | ▲ Buy | 422,087 | 0.08% | $1.55M | 2026-08-14 |
| Schonfeld Strategic Advisors LLC | ▲ Buy | 416,869 | 0.08% | $1.53M | 2026-08-14 |
| AllianceBernstein L.P. | ▲ Buy | 472,284 | 0.09% | $1.45M | 2026-08-14 |
| Balyasny Asset Management L.P. | ▲ Buy | 353,661 | 0.07% | $1.30M | 2026-08-14 |
| ExodusPoint Capital Management, LP | ▼ Sell | 248,783 | 0.05% | $913.0K | 2026-08-14 |
| Winton Group Ltd | ▲ Buy | 192,800 | 0.04% | $707.6K | 2026-08-07 |